Herceptin acts as an anti-angiogenic cocktail
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Malignant tumours secrete factors that enable them to commandeer their own blood supply (angiogenesis), and blocking the action of these factors can inhibit tumour growth. But because tumours may become resistant to treatments that target individual angiogenic factors by switching over to other angiogenic molecules, a cocktail of multiple anti-angiogenic agents should be more effective. Here we show that herceptin, a monoclonal antibody against the cell-surface receptor HER2 (for human epidermal growth factor receptor-2; ref. 4), induces normalization and regression of the vasculature in an experimental human breast tumour that overexpresses HER2 in mice, and that it works by modulating the effects of different pro- and anti-angiogenic factors. As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Certain molecularly targeted agents, such as the anti-HER2 antibody trastuzumab, and metronomic chemotherapy can also induce vascular normalization via upregulation of thrombospondin expression28,116,117.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [116]
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Self-citationLeakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1
Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T. N., Yancopoulos, G. D., & McDonald, D. M. (1999) · Science · doi:10.1126/science.286.5449.2511 · Cited by 1,359
Tumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Self-citationThrombospondins as matricellular modulators of cell function
Bornstein, P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12749 · Cited by 470
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2201 · Cited by 276
‘Accidental’ anti-angiogenic drugs
Kerbel, R. S., Viloria-Petit, A., Klement, G., & Rak, J. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00092-7 · Cited by 182
Angiogenic Heterogeneity: Regulation of Neoplastic Angiogenesis by the Organ Microenvironment
Fidler, I. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1040 · Cited by 109
Jain, R. K., & Carmeliet, P. (2001) · Scientific American · doi:10.1038/scientificamerican1201-38 · Cited by 94
Self-citation
Research works printed but not linked: 1
- Jain, R. K., Munn, L. L. & Fukumura, D. Nature Rev. Cancer (in the press).
Cited by
Items 301–400 of 622
Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host
Modica, M. D., Tagliabue, E., & Triulzi, T. (2017) · Disease Markers · doi:10.1155/2017/7849108 · Cited by 37
Humbert, O., Lasserre, M., Bertaut, A., Fumoleau, P., Coutant, C., Brunotte, F., & Cochet, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203075 · Cited by 37
Man, R., Jeelani, N., Zhou, C., & Yang, Y. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200516150345 · Cited by 38
Angiogenesis and Lymphangiogenesis in Tumors: Insights from Intravital MicroscopyPreprint
JAIN, R. K. (2002) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2002.67.239 · Cited by 34
Self-citationKim, B.-R., Seo, S. H., Park, M. S., Lee, S.-H., Kwon, Y., & Rho, S. B. (2015) · Oncotarget · doi:10.18632/oncotarget.5570 · Cited by 38
Whisenant, J. G., Sorace, A. G., McIntyre, J. O., Kang, H., Sanchez, V. M., Loveless, M. E., & Yankeelov, T. E. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.09.011 · Cited by 32
Modulating Tumor Vasculature through Signaling Inhibition to Improve Cytotoxic Therapy
Maity, A. M., & Bernhard, E. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3615 · Cited by 35
Metabolic pathway alterations in microvascular endothelial cells in response to hypoxia
Cohen, E. B., Geck, R. C., & Toker, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232072 · Cited by 33
Predictive Biomarkers in the Treatment of Her2-Positive Breast Cancer: An Ongoing Challenge
Triulzi, T., Bianchi, G., & Tagliabue, E. (2016) · Future Oncology · doi:10.2217/fon-2015-0025 · Cited by 35
Trastuzumab: In HER2-Positive Metastatic Gastric Cancer
Croxtall, J. D., & McKeage, K. (2010) · Drugs · doi:10.2165/11205900-000000000-00000 · Cited by 33
Nucleic acid combinations: A new frontier for cancer treatment
Remant Bahadur, K. C., Thapa, B., Valencia‐Serna, J., Aliabadi, H. M., & Uludağ, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.029 · Cited by 32
Smith, S. N., Schubert, R., Simic, B., Brücher, D., Schmid, M., Kirk, N., Freitag, P. C., Gradinaru, V., & Plückthun, A. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2017925118 · Cited by 26
ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter
Loureiro, R. M. B., Maharaj, A. S. R., Dankort, D. L., Muller, W. J., & D'Amore, P. A. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.053 · Cited by 36
Tripathy, D. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-375 · Cited by 36
Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma
Végran, F., Boidot, R., Coudert, B. P., Fumoleau, P., Arnould, L., Garnier, J., Causeret, S., Fraise, J., Dembélé, D., & Lizard‐Nacol, S. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605310 · Cited by 29
Isacoff, W. H., Reber, H. A., Bedford, R. A., Hoos, W. A., Rahib, L., Upfill-Brown, A. M., Donahue, T. R., & Hines, O. J. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0572-3 · Cited by 29
Syed, A., Woodall, R. T., Whisenant, J. G., Yankeelov, T. E., & Sorace, A. G. (2018) · Neoplasia · doi:10.1016/j.neo.2018.10.008 · Cited by 34
Recombinant antibodies for cancer therapy
Deonarain, M. P. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1123 · Cited by 35
Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts.
Izumi, Y., di Tomaso, E., Hooper, A. T., Huang, P., Huber, J., Hicklin, D. J., Fukumura, D., Jain, R. K., & Suit, H. D. (2003) · PubMed · Cited by 29
Self-citationBergers, G., & Hanahan, D. (2002) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2002.67.293 · Cited by 29
Wilson-O'Brien, A. L., DeHaan, C. L., & Rogers, S. (2007) · Endocrinology · doi:10.1210/en.2007-0985 · Cited by 28
Expression of HER-2 in Rectal Cancers Treated With Preoperative Radiotherapy
Yao, Y., Du, C., Chen, N., Chen, P., & Gu, J. F. (2014) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000107 · Cited by 28
Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality
Verma, S., Lavasani, S., Mackey, J., Pritchard, K. I., Clemons, M. J., Dent, S., Latreille, J., Lemieux, J., Provencher, L., Verma, S., et al. (2010) · Current Oncology · doi:10.3747/co.v17i4.700 · Cited by 28
Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors
Askoxylakis, V., Arvanitis, C., Wong, C. S. F., Ferraro, G. B., & Jain, R. K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.011 · Cited by 28
Self-citationKim, Y. R., Yudina, A., Figueiredo, J.-L., Reichardt, W., Hu‐Lowe, D. D., Petrovsky, A., Kang, H. W., Torres, D. M., Mahmood, U., Weissleder, R., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-2619 · Cited by 28
Márquez‐Garbán, D. C., Gorrín-Rivas, M. J., Chen, H., Sterling, C., Elashoff, D. A., Hamilton, N. M., & Pietras, R. J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.009 · Cited by 27
Yao, X., He, Z., Qin, C., Zhang, P., Sui, C., Deng, X., Fang, Y., Li, G., & Shi, J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01834-2 · Cited by 26
Antibodies for angiogenesis inhibition, vascular targeting and endothelial cell transcytosis
Trachsel, E., & Neri, D. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.11.002 · Cited by 26
Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy
Brumlik, M. J., Daniel, B. J., Waehler, R., Curiel, D. T., Giles, F. J., & Curiel, T. J. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.1.87 · Cited by 29
Neuregulin-1β regulation of embryonic endothelial progenitor cell survival
Safa, R., Peng, X., Pentassuglia, L., Lim, C. C., Lamparter, M., Silverstein, C. A., Walker, J., Chen, B., Geisberg, C. A., Hatzopoulos, A. K., et al. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01104.2009 · Cited by 28
Angiogenesis: prognostic and therapeutic implications in gynecologic and breast malignancies
Sauer, G., & Deißler, H. (2003) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200302000-00007 · Cited by 27
Goldstein, L. J., Zhao, F., Wang, Μ., Swaby, R. F., Sparano, J. A., Meropol, N. J., Bhalla, K. N., Pellegrino, C. M., Alpaugh, R. K., Falkson, C. I., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4310-9 · Cited by 29
Benedetto, M. D., Starzec, A. B., Vassy, R., Perret, G. Y., Crépin, M., & Kraemer, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600985 · Cited by 26
Dragowska, W. H., Warburton, C., Yapp, D. T. T., Minchinton, A. I., Hu, Y., Waterhouse, D., Gelmon, K. A., Skov, K. A., Woo, J., Masin, D., et al. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.606.2.11 · Cited by 26
Zhu, Q., Tannenbaum, S. H., Kurtzman, S. H., DeFusco, P. A., Ricci, A., Vavadi, H., Zhou, F., Chen, X., Merkulov, A., Hegde, P., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0975-1 · Cited by 27
Cl??menceau, B., Gallot, G., Vivien, R., Gaschet, J., Campone, M., & Vi??, H. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175686.13368.5c · Cited by 25
Yuan, Q., Simmons, H. H., Robinson, M. K., Russeva, M., Marasco, W. A., & Adams, G. P. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0115 · Cited by 25
Huang, Y., Le, J., Miao, A., Zhi, W., Wang, F., Chen, Y., Zhou, S., & Chang, C. (2021) · Gland Surgery · doi:10.21037/gs-20-836 · Cited by 23
Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies
Mata, J. J., Rebollo-Liceaga, J., Martinez-Navarro, E., Manzano, R. G., Brugarolas, A., Juan, M., & Sureda, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.926289 · Cited by 28
The epidermal growth factor receptor family in breast cancer
Koutras, A. K., & Evans, T. R. J. (2008) · OncoTargets and Therapy · doi:10.2147/ott.s3842 · Cited by 32
Gefitinib–trastuzumab combination on hormone-refractory prostate cancer xenograft
Formento, P., Hannoun‐Lévi, J., Gérard, F., Mazeau, C., Fischel, J., Étienne-Grimaldi, M.-C., Gugenheim, J., & Milano, G. A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.03.021 · Cited by 23
New HER2-Positive Targeting Agents in Clinical Practice
Tolaney, S. M. (2014) · Current Oncology Reports · doi:10.1007/s11912-013-0359-8 · Cited by 23
Pilancı, K. N., Alço, G., Ordu, Ç., Sarsenov, D., Çelebi, F., Erdogan, Z., Ağaçayak, F., İlgün, S., Tecimer, C., Demir, G., et al. (2015) · Medicine · doi:10.1097/md.0000000000000671 · Cited by 22
Bloom, M. J., Jarrett, A. M., Triplett, T., Syed, A., Davis, T., Yankeelov, T. E., & Sorace, A. G. (2020) · BMC Cancer · doi:10.1186/s12885-020-06868-4 · Cited by 23
Pereira, M., Matuszewska, K., Jamieson, C., & Petrik, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.772349 · Cited by 23
Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer
Liu, J., He, M., Wang, Z., Li, Q., & Xu, B. (2022) · Oncology Research and Treatment · doi:10.1159/000526481 · Cited by 23
Cardio-oncology: Cardiovascular Complications of Cancer Therapy
Henning, R. J., & Harbison, R. D. (2017) · Future Cardiology · doi:10.2217/fca-2016-0081 · Cited by 22
Stress alleviation strategy in cancer treatment: Insights from a mathematical model
Mpekris, F., Voutouri, C., Papageorgis, P., & Stylianopoulos, T. (2018) · ZAMM ‐ Journal of Applied Mathematics and Mechanics / Zeitschrift für Angewandte Mathematik und Mechanik · doi:10.1002/zamm.201700270 · Cited by 24
Antineovascular therapy, a novel antiangiogenic approach
Shimizu, K., Asai, T., & Oku, N. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.1.63 · Cited by 21
Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?
Bottos, A., & Bardelli, A. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1331-3 · Cited by 24
Hardee, M. E., Eapen, R. J., Rabbani, Z. N., Dreher, M. R., Marks, J. R., Blackwell, K., & Dewhirst, M. W. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0729-3 · Cited by 20
Binding of Trastuzumab to ErbB2 Is Inhibited by a High Pericellular Density of Hyaluronan
Váradi, T., Mersich, T., Auvinen, P., Tammi, R., Tammi, M., Salamon, F., Besznyák, I., Jakab, F., Baranyai, Z., Szöllõsi, J., et al. (2012) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155412448070 · Cited by 22
Alaoui‐Jamali, M. A., & Qiang, H. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00024-4 · Cited by 21
Oncogenes and Tumor Angiogenesis
Rak, J. W., & Kerbel, R. S. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-313-2_10 · Cited by 21
Arteaga, C. L. (2003) · PubMed · Cited by 20
Antibody Therapeutics in Oncology
Wold, E. D., Smider, V. V., & Felding, B. H. (2016) · Immunotherapy Open Access · doi:10.4172/2471-9552.1000108 · Cited by 19
Pertuzumab In Her2-Positive Early Breast Cancer: Current Use And Perspectives
Eiger, D., Ponde, N. F., & de Azambuja, E. (2019) · Future Oncology · doi:10.2217/fon-2018-0896 · Cited by 18
Kaya, M. K., Demır, T., Bulut, H., Akpolat, N., & Turgut, B. (2015) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12500 · Cited by 19
The Role of her2-Targeted Therapies in Women with her2-Overexpressing Metastatic Breast Cancer
Dent, S. F., Verma, S., Latreille, J., Rayson, D., Clemons, M. J., Mackey, J. R., Verma, S., Lemieux, J., Provencher, L., Chia, S., et al. (2009) · Current Oncology · doi:10.3747/co.v16i4.469 · Cited by 20
Trastuzumab: updates and future issues
Toi, M., Horiguchi, K., Bando, H., Saji, S., & Chow, L. W. C. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0110-8 · Cited by 19
Deregulation of HER2 Downstream Signaling in Breast Cancer Cells by a Cocktail of Anti-HER2 scFvs
Nejatollahi, F., Ranjbar, R., Younesi, V., & Asgharpour, M. (2013) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504013x13657689382734 · Cited by 18
Deng, P., Hu, C., Xiong, Z., Li, Y., Jiang, J., Yang, H., Tang, Y., Cao, L., & Lu, R. (2019) · Cancer Management and Research · doi:10.2147/cmar.s187750 · Cited by 18
Optimizing combination therapy in a murine model of HER2+ breast cancer
Lima, E. A. B. F., Wyde, R. A. F., Sorace, A. G., & Yankeelov, T. E. (2022) · Computer Methods in Applied Mechanics and Engineering · doi:10.1016/j.cma.2022.115484 · Cited by 19
Park, C.-Y., Kim, K., Kim, Y., Zhu, R., Hain, L., Seferovic, H., Kim, M., Woo, H. J., Hwang, H., Lee, S. H., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c00360 · Cited by 18
Resistance to HER2-targeted therapies: a potential role for FOXM1
Peake, B. F., & Nahta, R. (2014) · Breast Cancer Management · doi:10.2217/bmt.14.33 · Cited by 21
Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer
Brunello, A., Roma, A., Falci, C., & Basso, U. (2008) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489208786242313 · Cited by 18
Reversible posterior leukoencephalopathy syndrome and trastuzumab
Kaneda, H., Okamoto, I., Satoh, T., & Nakagawa, K. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9696-3 · Cited by 18
Vascular and Interstitial Biology of Tumors
Jain, R. K., Chauhan, V. P., & Duda, D. G. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00008-4 · Cited by 21
Self-citationDoxorubicin Expands in Vivo Secretion of Circulating Exosome in Mice
Emam, S. E., Ando, H., Lila, A. S. A., Kobayashi, S., Shimizu, T., Okuhira, K., Ishima, Y., & Ishida, T. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00202 · Cited by 19
Kałas, W., Gilpin, S. E., Yu, J., May, L. L., Krchnakova, H., BORNSTEIN, P. K., & Rak, J. W. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.128 · Cited by 18
A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity
Deng, W., Liu, J., Pan, H., Li, L., Zhou, C., Wang, X., Shu, R., Dong, B., Cao, D., Li, Q., et al. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000200 · Cited by 17
Shen, Y., Fujii, T., Ueno, N. T., Tripathy, D., Fu, N., Zhou, H., Ning, J., & Xiao, L. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4969-6 · Cited by 18
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells
Hua, J., Zhang, Z., Zhang, L., Sun, Y., & Yuan, Y. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04303-4 · Cited by 17
Recognition of tumor blood vessel normalization as a new antiangiogenic concept
Hellmann, K. (2004) · Nature Medicine · doi:10.1038/nm0404-329a · Cited by 17
The role of tumor-derived exosomes in tumor angiogenesis and tumor progression
Głuszko, A., Mirza, S. M., Piszczatowska, K., Kantor, I., Struga, M., & Szczepański, M. J. (2019) · Current Issues in Pharmacy and Medical Sciences · doi:10.2478/cipms-2019-0034 · Cited by 17
Biomechanical regulation of planar cell polarity in endothelial cells
Wang, C., Qu, K., Wang, J., Qin, R., Li, B., Qiu, J., & Wang, G. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166495 · Cited by 18
Chen, Y., Goudar, V. S., Wu, R., Hsieh, H.-Y., Yang, C., Chang, H., Lee, G., Ho, C., & Tseng, F. (2016) · RSC Advances · doi:10.1039/c6ra01733a · Cited by 16
Fu, X., Zhang, Y., Yang, J., Qi, Y., Ming, Y., Sun, M., Shang, Y., Yang, Y., Zhu, X., & Gao, Q. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s174138 · Cited by 17
New developments in the treatment of HER2-positive breast cancer
Nahta, R. (2012) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s24976 · Cited by 19
Herceptin and breast cancer: An overview for surgeons
Patani, N., & Mokbel, K. (2008) · Surgical Oncology · doi:10.1016/j.suronc.2008.11.001 · Cited by 16
Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab
Munzone, E., Nolè, F., Sanna, G., & Goldhirsch, A. (2004) · The Breast · doi:10.1016/j.breast.2004.08.019 · Cited by 16
Targeted Cancer Therapy: Promise and Reality
Klein, S., & Levitzki, A. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97013-4 · Cited by 17
Pertuzumab in gastrointestinal cancer
Oh, D., & Bang, Y. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1126578 · Cited by 15
Measuring Vascular Permeability In Vivo
Meijer, E. F. J., Baish, J. W., Padera, T. P., & Fukumura, D. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3801-8_6 · Cited by 17
Self-citationMolinelli, C., Parisi, F., Razeti, M. G., Arecco, L., Cosso, M., Fregatti, P., Mastro, L. D., Poggio, F. B., & Lambertini, M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1857243 · Cited by 15
Molecular Biology of Breast Cancer
Aftimos, P. G., Azim, H. A., & Sotiriou, C. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802761-5.00026-2 · Cited by 16
Zou, Z., Bidu, C., Bellenger, S., Narce, M., & Bellenger, J. (2013) · Biochimie · doi:10.1016/j.biochi.2013.08.021 · Cited by 17
Nagaraja, T. N., Aryal, M. P., Brown, S. L., Bagher‐Ebadian, H., Mikkelsen, T., Yang, J. J., Panda, S., Keenan, K. A., Cabral, G., & Ewing, J. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084493 · Cited by 16
Ji, B., Chen, B., Wang, T., Song, Y., Chen, M., Ji, T., Wang, X., Gao, S., & Ma, Q. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3062-1 · Cited by 15
Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
Morris, S. R., & Carey, L. (2006) · PubMed · Cited by 21
Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies
Almeida, C. F., Correia‐da‐Silva, G., Teixeira, N. A. A., & Amaral, C. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116178 · Cited by 18
Using monoclonal antibodies to stimulate antitumor cellular immunity
Durrant, L. G., Pudney, V. A., & Spendlove, I. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.33 · Cited by 14
Arai, R. J., Petry, V., Hoff, P. M., & Mano, M. S. (2018) · Biomarker Research · doi:10.1186/s40364-018-0135-x · Cited by 14
Signal Transduction Therapy for Cancer - Whither Now?
Klein, S., & Levitzki, A. (2006) · Current Signal Transduction Therapy · doi:10.2174/157436206775269244 · Cited by 16
Circulating biomarkers from tumour bulk to tumour machinery: promises and pitfalls
Gion, M., & Daidone, M. G. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.07.031 · Cited by 16
Trastuzumab: In HER2 and Hormone Receptor Co-Positive Metastatic Breast Cancer
Orman, J. S., & Perry, C. M. (2007) · Drugs · doi:10.2165/00003495-200767180-00009 · Cited by 14
ADCC enhancement: A conundrum or a boon to mAb therapy?
Narvekar, A., Pardeshi, A., Jain, R. D., & Dandekar, P. P. (2022) · Biologicals · doi:10.1016/j.biologicals.2022.08.006 · Cited by 15
Self-citationMason, J. K., Fu, M., Chen, J., Yu, Z. S., & Thompson, L. U. (2013) · Nutrition and Cancer · doi:10.1080/01635581.2013.756921 · Cited by 13
Lu, D., Guo, Y., Hu, Y., Wang, M., Li, C., Gangrade, A., Chen, J., Zheng, Z., & Guo, J. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17001 · Cited by 13
Nm23-H1/nucleoside diphosphate kinase as a key molecule in breast tumor angiogenesis
Youn, B., Kim, H. D., & Kim, J. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.11.1419 · Cited by 13
Metadata
- Authors
- Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature
- Published
- 2002-03
- Volume
- 416
- Issue
- 6878
- Pages
- 279-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2034801324
- Cited by
- 623
- References
- 11
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 26 · 2023: 10 · 2022: 14 · 2021: 12 · 2020: 18 · 2019: 12 · 2018: 20 · 2017: 23 · 2016: 18 · 2015: 24 · 2014: 27 · 2013: 30 · 2012: 35
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (P01CA080124)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- trastuzumab, anti-angiogenic therapy, HER2, human epidermal growth factor receptor 2, tumor angiogenesis, tumor regression, combination therapy, breast cancer, monoclonal antibodies, tumor resistance
- MeSH terms
- Trastuzumab, Animals, Antibodies, Monoclonal, Humans, Lymphokines, Mammary Neoplasms, Experimental, Neovascularization, Pathologic, Signal Transduction, Gene Expression, Endothelial Growth Factors, Mice, SCID, Genes, erbB-2, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.